Sirtex Medical launches SIR-Spheres microspheres in Latin America


Sirtex Medical has announced the treatment of the first patients in Latin America with its SIR-Spheres microspheres used in the treatment of inoperable liver tumours. The first procedure took place on 10 October at the Hospital Italiano de Buenos Aires, Argentina, which is the first centre to offer the therapy in Latin America. 

“The radioactive microspheres are a powerful resource for treating unresectable primary and secondary tumours,” said Ricardo García-Mónaco, head of Angiography and Endovascular Therapy, Hospital Italiano de Buenos Aires. “This new treatment is used singly or combined with other therapies, providing excellent results and allowing patients to maintain a good quality of life.”            

“Sirtex’s expansion into Latin America is a pivotal step in our strategy to bring the SIR-Spheres microspheres treatment to more patients who will benefit from this technology,” said Michael Mangano, president of Sirtex Medical. “In the past, patients with inoperable liver tumours in Latin America have had few options and selective internal radiation therapy (SIRT) has not been available. We look forward to working with our partner physicians and hospitals to help implement SIR-Spheres microspheres programmes and expand the level of care they are able to provide in this region.”

Sirtex recently received regulatory approval for SIR-Spheres microspheres from the Argentinean National Administration of Drugs, Food & Medical Technology (ANMAT). Sirtex will provide training and support for hospitals in Latin America to administer SIR-Spheres microspheres. The company anticipates expanding the availability of SIR-Spheres microspheres in additional centres in Argentina and countries in Latin America in the upcoming months.

SIR-Spheres microspheres are approved for use in Australia, United States, Europe and Argentina. Additionally, SIR-Spheres microspheres are supplied in countries such as Hong Kong, Malaysia, Singapore, Thailand, Taiwan, India, Israel, and Turkey.